About TEZCAT Laboratories:
TEZCAT Laboratories is committed to the research and development of novel biologic-based therapies to treat Ras pathway-activated cancers with high unmet needs. The first-generation technology has been optimized for tumor-specific killing, solid tumor penetration, and manufacturability.
Born out of NYU Langone Health, our team is committed to refining and delivering the leading-edge technology from bench to bedside. TEZCAT Laboratories has participated in the following programs:
TEZCAT Laboratories is committed to the research and development of novel biologic-based therapies to treat Ras pathway-activated cancers with high unmet needs. The first-generation technology has been optimized for tumor-specific killing, solid tumor penetration, and manufacturability.
Born out of NYU Langone Health, our team is committed to refining and delivering the leading-edge technology from bench to bedside. TEZCAT Laboratories has participated in the following programs:
- 2018 Entrepreneurship Lab (ELab) Program, an initiative of NYC's Economic Development Corporation (NYCEDC).
- 2020 JLABs Virtual Program, part of Johnson & Johnson Innovation
- 2021 TMC Accelerator for Cancer Therapeutics, part of TMC Innovation and funded by Cancer Prevention and Research Institute of Texas (CPRIT)
